vs
Side-by-side financial comparison of ESCO TECHNOLOGIES INC (ESE) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $158.6M, roughly 1.8× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 9.9%, a 61.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 17.3%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $63.0M).
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
ESE vs STOK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $289.7M | $158.6M |
| Net Profit | $28.7M | $112.9M |
| Gross Margin | 41.4% | — |
| Operating Margin | 13.2% | 70.2% |
| Net Margin | 9.9% | 71.2% |
| Revenue YoY | 17.3% | 3661.1% |
| Net Profit YoY | 22.2% | 528.0% |
| EPS (diluted) | $1.11 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $289.7M | — | ||
| Q3 25 | $286.5M | — | ||
| Q2 25 | $296.3M | — | ||
| Q1 25 | $265.5M | $158.6M | ||
| Q4 24 | $247.0M | $22.6M | ||
| Q3 24 | $298.5M | — | ||
| Q2 24 | $260.8M | — | ||
| Q1 24 | $249.1M | — |
| Q4 25 | $28.7M | — | ||
| Q3 25 | $218.7M | — | ||
| Q2 25 | $26.1M | — | ||
| Q1 25 | $31.0M | $112.9M | ||
| Q4 24 | $23.5M | $-10.5M | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $29.2M | — | ||
| Q1 24 | $23.2M | — |
| Q4 25 | 41.4% | — | ||
| Q3 25 | 45.9% | — | ||
| Q2 25 | 41.2% | — | ||
| Q1 25 | 41.1% | — | ||
| Q4 24 | 39.8% | — | ||
| Q3 24 | 40.1% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 38.8% | — |
| Q4 25 | 13.2% | — | ||
| Q3 25 | 17.2% | — | ||
| Q2 25 | 11.2% | — | ||
| Q1 25 | 15.3% | 70.2% | ||
| Q4 24 | 11.4% | -60.4% | ||
| Q3 24 | 14.8% | — | ||
| Q2 24 | 14.3% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 76.3% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 11.7% | 71.2% | ||
| Q4 24 | 9.5% | -46.4% | ||
| Q3 24 | 11.5% | — | ||
| Q2 24 | 11.2% | — | ||
| Q1 24 | 9.3% | — |
| Q4 25 | $1.11 | — | ||
| Q3 25 | $8.43 | — | ||
| Q2 25 | $1.01 | — | ||
| Q1 25 | $1.20 | $1.90 | ||
| Q4 24 | $0.91 | $-0.15 | ||
| Q3 24 | $1.32 | — | ||
| Q2 24 | $1.13 | — | ||
| Q1 24 | $0.90 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.8M | $274.8M |
| Total DebtLower is stronger | $145.5M | — |
| Stockholders' EquityBook value | $1.6B | $350.1M |
| Total Assets | $2.4B | $406.9M |
| Debt / EquityLower = less leverage | 0.09× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.8M | — | ||
| Q3 25 | $101.3M | — | ||
| Q2 25 | $78.7M | — | ||
| Q1 25 | $57.4M | $274.8M | ||
| Q4 24 | $71.3M | $128.0M | ||
| Q3 24 | $66.0M | — | ||
| Q2 24 | $63.0M | — | ||
| Q1 24 | $59.4M | — |
| Q4 25 | $145.5M | — | ||
| Q3 25 | $186.0M | — | ||
| Q2 25 | $525.0M | — | ||
| Q1 25 | $88.0M | — | ||
| Q4 24 | $112.0M | — | ||
| Q3 24 | $122.0M | — | ||
| Q2 24 | $173.0M | — | ||
| Q1 24 | $191.0M | — |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.3B | $350.1M | ||
| Q4 24 | $1.2B | $229.0M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $1.8B | $406.9M | ||
| Q4 24 | $1.8B | $271.6M | ||
| Q3 24 | $1.8B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $1.8B | — |
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | 0.07× | — | ||
| Q4 24 | 0.09× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.9M | $131.8M |
| Free Cash FlowOCF − Capex | $63.0M | $131.7M |
| FCF MarginFCF / Revenue | 21.7% | 83.0% |
| Capex IntensityCapex / Revenue | 2.0% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.40× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $239.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.9M | — | ||
| Q3 25 | $109.9M | — | ||
| Q2 25 | $73.7M | — | ||
| Q1 25 | $24.1M | $131.8M | ||
| Q4 24 | $34.2M | $-23.2M | ||
| Q3 24 | $72.1M | — | ||
| Q2 24 | $36.2M | — | ||
| Q1 24 | $10.5M | — |
| Q4 25 | $63.0M | — | ||
| Q3 25 | $97.8M | — | ||
| Q2 25 | $64.9M | — | ||
| Q1 25 | $14.0M | $131.7M | ||
| Q4 24 | $29.0M | $-23.2M | ||
| Q3 24 | $60.9M | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | 21.7% | — | ||
| Q3 25 | 34.1% | — | ||
| Q2 25 | 21.9% | — | ||
| Q1 25 | 5.3% | 83.0% | ||
| Q4 24 | 11.7% | -102.7% | ||
| Q3 24 | 20.4% | — | ||
| Q2 24 | 10.6% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 3.8% | 0.1% | ||
| Q4 24 | 2.1% | 0.2% | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 2.40× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | 0.78× | 1.17× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
STOK
Segment breakdown not available.
